BETHESDA, Maryland, September 12 /PRNewswire/ --

- UBC ClinResearch to Expand Global Reach in Pioneering Field

United BioSource Corporation (UBC) today announced the acquisition of an
ownership interest in ClinResearch GmbH, a global leader in technology
solutions and services for flexible, or adaptive, clinical trials.
Headquartered in Cologne, Germany, with more than 100 employees, ClinResearch
has designed and implemented 80 adaptive programs over the past seven years.
ClinResearch's co-founder, Reinhard Eisebitt, is a co-developer of the
leading software used by pharmaceutical companies and contract research
organizations (CROs) throughout the world to support the rigorous statistical
requirements of adaptive trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

ClinResearch, which will now operate under the name UBC ClinResearch,
will be a centerpiece of UBC's adaptive design clinical trial offering and
will deliver a full service, global solution for pharmaceutical,
biotechnology and medical device companies seeking to capitalize on the
benefits of adaptive design in their clinical development strategy.

"We are thrilled to welcome ClinResearch to the UBC family," said Ethan
Leder, CEO of UBC. "Having worked with the founders for several years, we
know that they are an excellent fit with our culture and vision. They are
innovative and science driven, and have built a world-class organization with
a track record of developing and executing technology solutions that we plan
to introduce aggressively to our growing base of sponsor and CRO clients."

"The interest in adaptive design is accelerating from the early adopter
to the rapid growth stage. We are excited to be joining an organization with
the resources to allow us to capitalize on this opportunity," noted Michael
Fischer, PhD, founder of ClinResearch. Fischer added, "We are moving forward
with expansion plans to fulfill demand on our global projects with UBC and
anticipate growth in Cologne, as well as in our offices in Russia and the
Ukraine to benefit our clients."

According to Patrick Lindsay, Executive Vice President of UBC,
"ClinResearch's leadership in adaptive design is consistent with UBC's focus
on innovative solutions for clinical development. Reinhard Eisebitt,
ClinResearch's co-founder, is recognized by the FDA and European regulatory
authorities as a thought leader in adaptive design based on the proprietary
software and techniques that he helped develop. We look forward to bringing
our combined strengths in this novel and quickly evolving methodology to the
industry." The ClinResearch announcement is the latest in a series of
transactions made since UBC raised US$153 million in equity capital from a
syndicate of leading private equity firms in 2003.

Since 1999, ClinResearch, GmbH, headquartered in Cologne, Germany, has
been a leader in planning, conducting and reporting clinical studies for the
pharmaceutical and medical device industries. For more information, visit
www.clinresearch.com.

United BioSource Corporation (UBC) is a global pharmaceutical services
organization that helps emerging and established life science companies
develop and commercialize medical products. UBC specializes in offering new
and innovative ways to study drugs and devices by offering expertise in
science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United
States, Canada, Europe and South America. For more information, visit
www.unitedbiosource.com or call +1-866-458-1096.

CONTACT: Tess Drahzal, +1-(240)-644-0420, info@unitedbiosource.com

Web site: http://www.unitedbiosource.com